The Promise of Generative AI in Clinical Development

A majority of enterprises consider generative AI a strategic priority for their clinical development businesses, and anticipate a significant increase in spending on gen AI initiatives in the next 3-5 years. This high demand is fueled by the potential to improve cost and operational efficiencies and enhance stakeholder experience. This Viewpoint shares Everest’s findings from a survey of 50 clinical trial stakeholders on their expectations from gen AI. The report provides:

  • A deeper understanding of pharma enterprises’ gen AI objectives
  • Investment strategies and procurement initiatives for implementing gen AI solutions
  • Potential business value of gen AI use cases in clinical development
  • Challenges preventing gen AI’s adoption in clinical development
  • An enterprise framework to adopt and scale gen AI initiatives